(Total Views: 608)
Posted On: 06/07/2021 9:02:36 AM
Post# of 72440
Another reason we need Brilacidin. I have reviewed the viruses article again.
The in vitro tests are just for a few hours, but Brilacidin will be dosed over 5 days which should result in virtual elimination of Covid 19 very quickly. Its virucidal property will be accentuated by its direct antiviral action in the plasma since Brilacidin is not a prodrug.
Brilacidins half life is long, not short, and has been reported to be up to 23 hours with "consistent and linear pharmacokinetics in plasma"
Remember in ABSSI one IV dose of Brilacidin was equivalent to 1 week of Daptomycin.
https://static1.squarespace.com/static/571535...BSSSI1.pdf
The IC 50 dose is .565 um; IC 90 was 2.63 um while the maximum serum level in ABBSI was 7.67 um at .6mg/kg
Brilacidin's serum level is 13.5 greater than the IC50 and 3 times greater than the IC90 which should give a nice margin of effectiveness against Covid19 with Brilacidin's long half life . In addition the peak and trough levels should increase with each IV dose.
Fortunately safety is not a concern with Brilacidin.The paresthesias were all transient and the BP would be easily treatable if it became elevated to significant levels.Neither should play a significant role when treating a life threatening disease like Covid19.
Of course all of this is a guess at this point since we do not know the dose given in the phase 2 clinical trial.
It is possible the most important attribute of Brilacidin for Covid19 could prove to be its anti-inflammatory properties.
We will find out when the Phase 2 results are available.
GLTA,Farrell
The in vitro tests are just for a few hours, but Brilacidin will be dosed over 5 days which should result in virtual elimination of Covid 19 very quickly. Its virucidal property will be accentuated by its direct antiviral action in the plasma since Brilacidin is not a prodrug.
Brilacidins half life is long, not short, and has been reported to be up to 23 hours with "consistent and linear pharmacokinetics in plasma"
Remember in ABSSI one IV dose of Brilacidin was equivalent to 1 week of Daptomycin.
https://static1.squarespace.com/static/571535...BSSSI1.pdf
The IC 50 dose is .565 um; IC 90 was 2.63 um while the maximum serum level in ABBSI was 7.67 um at .6mg/kg
Brilacidin's serum level is 13.5 greater than the IC50 and 3 times greater than the IC90 which should give a nice margin of effectiveness against Covid19 with Brilacidin's long half life . In addition the peak and trough levels should increase with each IV dose.
Fortunately safety is not a concern with Brilacidin.The paresthesias were all transient and the BP would be easily treatable if it became elevated to significant levels.Neither should play a significant role when treating a life threatening disease like Covid19.
Of course all of this is a guess at this point since we do not know the dose given in the phase 2 clinical trial.
It is possible the most important attribute of Brilacidin for Covid19 could prove to be its anti-inflammatory properties.
We will find out when the Phase 2 results are available.
GLTA,Farrell
(13)
(0)Scroll down for more posts ▼
